Psoriasis is a chronic, inflammatory, autoimmune skin disease that can affect children, adolescents, and adults. Although adult psoriasis and pediatric psoriasis are similar, effective management of pediatric psoriasis is more challenging owing to the limited number of treatments approved for children. Only four biologics—Amgen’s Enbrel, Janssen’s Stelara, Eli Lilly’s Taltz, and Novartis’s Cosentyx—are approved to treat pediatric and adolescent patients with psoriasis. Although topical corticosteroids continue to be the mainstay of pediatric treatment, this class is expected to face competition from a recently approved nonsteroidal topical cream, Arcutis Biotherapeutics’ Zoryve, in patients 12 years or older. Additionally, the use of biologics is gradually increasing in pediatric patients, especially in the later lines, owing to the more-frequent and severe adverse events associated with long-term use of topical corticosteroids in children. Nevertheless, significant unmet need remains for efficacious therapies with better safety profiles for this psoriasis subpopulation.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: AbbVie, Amgen, Arcutis, Astellas, Bausch Health, Eli Lilly, Janssen, Novartis.
Key drugs: Cosentyx, Elidel, Enbrel, Humira, Remicade, Skyrizi, Stelara, Taclonex, Taltz, Tremfya, Zoryve
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and optional quarterly data refreshes.